Disclosed are methods of treating mycobacteria infections, such as nontuberculosis mycobacterial (NTM) lung disease and pulmonary tuberculosis, including refractory lung disease, by orally administering encochleated antibiotics, including aminoglycosides, such as amikacin. Orally administered antibiotic cochleates have significantly reduced toxicity as compared to intravenously administered antibiotics.
